Validation data for Anti-CoV2RBD-c2-hlgG1 (clone B38)


https://www.invivogen.com/sars2-spike-b38-mab

For research use only

Version 21B01-ED

Anti-CoV2RBD-c2-hlgG1 is a recombinant monoclonal antibody (mAb) featuring the variable region of the SARS-CoV-2 spike mAb (clone B38), which specifically targets the SARS-CoV-2 Spike receptor-binding domain (RBD), and the constant region of the human lgG1 (hlgG1) isotype. The binding of the antibody has been validated by ELISA using a coated Spike-RBD-His fusion peptide (**Figure 1**). Infection of InvivoGen's HEK-Blue[™] hACE2 cells by SARS-CoV-2 Spike-(G614-variant)-pseudotyped lentiviral particles was successfully neutralized by Anti-CoV2RBD-c2-hlgG1 (clone B38) (**Figure 2**).

Binding of Anti-CoV2RBD-c2-hlgG1 to SARS-CoV-2 spike RBD by ELISA



Anti-CoV2RBD-c2-hIgG1 inhibits infection of HEK293 cells by Spike-pseudotyped lentiviral particles




Figure 2: Inhibition of infection by SARS-CoV-2 spike (G614-variant) pseudotyped lentiviral particles. Anti-CoV2RBD-c2-hlgG1 (clone B38), Anti-COV2RBD-c1-hlgG1 (clone H4), or a cocktail of both mAbs was incubated with SARS-CoV-2 spike-(G614-variant)-pseudotyped lentiviral particles for 1 hour at 37°C. Following this, HEK-Blue™ hACE2 cells were added and incubated for a further 72 hours. Infection by the pseudotyped particles (GFP-expression) was then measured using flow cytometry. Data are presented as % inhibition compared to the antibody-negative control.

TECHNICAL SUPPORT InvivoGen USA (Toll-Free): 888-457-5873 InvivoGen USA (International): +1 (858) 457-5873 InvivoGen Europe: +33 (0) 5-62-71-69-39 InvivoGen Hong Kong: +852 3-622-34-80 E-mail: info@invivogen.com

